Business Context and Reporting Period
This Form 8-K filing by Crane Co. (NYSE: CR) was submitted on October 25, 2021. The report primarily serves to announce the Company's results of operations for the quarter ended September 30, 2021, and to disclose a new share repurchase authorization approved by the Board of Directors.
Key Financial Metrics and Asbestos Liability
While specific revenue, profit, and cash flow figures for the quarter are referenced in an attached press release (Exhibit 99.1) and not detailed in the text of this filing, the document provides extensive data regarding asbestos-related liabilities and costs.
- Asbestos Liability Reserve: $630 million as of September 30, 2021 (down from $670 million as of December 31, 2020).
- Current Portion of Liability: $66.5 million, representing the best estimate of costs expected to be paid within the next twelve months.
- Insurance Recovery Asset: $77 million as of September 30, 2021 (down from $87 million as of December 31, 2020).
- Pending Claims: 29,926 total claims as of September 30, 2021. Approximately 18,000 are pending in New York, with roughly 16,000 being inactive non-malignancy claims filed over 15 years ago.
- Costs Incurred (9 months ended Sept 30, 2021): $35.7 million total (Settlement/indemnity: $24.5 million; Defense: $11.2 million).
- Net Cash Payments (9 months ended Sept 30, 2021): $29.6 million (after insurance receipts).
Material Changes and Share Repurchase
The filing discloses a significant capital allocation decision: the Board of Directors approved a new $300 million share repurchase authorization. Repurchases may occur via open market transactions or other means, with timing and amounts determined by management based on market conditions. There is no guarantee regarding the number of shares to be repurchased.
Regarding asbestos activity, the number of new claims filed in the three months ended September 30, 2021, was 795, compared to 707 in the same period in 2020. Settlements and dismissals also increased year-over-year in the quarter.
Outlook, Risks, and Contingencies
Asbestos Liability Methodology: The Company utilizes an independent actuarial firm to estimate liabilities through 2059. The estimate is driven by four primary factors: the number of new mesothelioma claims, average settlement costs for mesothelioma, the percentage of mesothelioma claims dismissed, and aggregate defense costs.
Insurance Coverage: The Company has settled with all but two of its solvent excess insurers. The model forecasts that approximately 14% of the total liability will be reimbursed by insurers. The Company notes that actual reimbursements vary and will decline over time.
Risks and Uncertainties: Management highlights significant uncertainties in estimating ultimate exposure. Variables include the timing and severity of claims, legislative changes, judicial rulings, and the financial viability of insurers. A significant upward trend in claims or costs could materially affect the estimated liability and financial results.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q3 2021 revenue, net income, and cash flow figures not included in this text.
- Monitor the execution of the new $300 million share repurchase program and its impact on liquidity.
- Track the quarterly trend in asbestos claims filed versus dismissed, specifically the ratio of mesothelioma to non-malignancy claims.
- Verify the status of negotiations with the two remaining solvent excess insurers regarding coverage agreements.
- Assess the impact of the $66.5 million current portion of the asbestos liability on near-term cash flow projections.